The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Acetylcholinesterase inhibitors in Alzheimer’s disease
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another target of miR-132 is acetylcholinesterase (ACHE), which encodes an enzyme responsible for the breakdown of the neurotransmitter acetylcholine at the neural synapse [37].”
From miR-10b-5p expression in Huntington’s disease brain relates to age of onset and the extent of striatal involvement (2015) · cites this paper as [37]
In the citing paper
“Acetylcholinesterase is critically involved in cognition”
From miR-10b-5p expression in Huntington’s disease brain relates to age of onset and the extent of striatal involvement (2015) · cites this paper as [37]
In the citing paper
“acetylcholinesterase inhibitors are FDA-approved for the treatment of cognitive impairments in Alzheimer’s disease [37].”
From miR-10b-5p expression in Huntington’s disease brain relates to age of onset and the extent of striatal involvement (2015) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living
Lawton, M. P., & Brody, E. M. (1969) · The Gerontologist · doi:10.1093/geront/9.3_part_1.179 · Cited by 18,540
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Hepatotoxic Effects of Tacrine Administration in Patients With Alzheimer's Disease
Watkins, P. B. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510370044030 · Cited by 829
Flagged first, then by citations
Research works printed but not linked: 48
- Khann G, 1984, Clinical diagnosis of Alzheimer’s disease: report of the NINCDS‐ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease., Neurology, 34, 939, 10.1212/WNL.34.7.939 · DOI · Paper page
- Katzman R, 1991, Advances in Alzheimer’s Disease., FASEB J, 5, 278, 10.1096/fasebj.5.3.2001787 · DOI
- BeckerREBecker RE Giacobini E editors.Cholinergic Basis of Alzheimer Therapy. Boston: Berkhauser 1991. Therapy of the cognitive deficit in Alzheimer’s disease; the cholinergic system. p. 1–22. · DOI
- CutlerNR SramekJJ VeroffAEAlzheimer’s Disease. Chichester: John Wiley and Sons 1994.
- 10.1002/ddr.430120302 · DOI
- 10.2165/00002512-199711060-00004 · DOI
- 10.3109/00048678609161337 · DOI
- 10.1176/ajp.141.11.1356 · DOI · Paper page
- 10.1176/ajp.151.3.390 · DOI · Paper page
- Kramer‐Ginsberg E, 1988, Clinical predictors of course for Alzheimer patients in a longitudinal study: a preliminary report., Psychopharmacol Bull, 24, 458
- 10.1002/ana.410310303 · DOI
- 10.1016/0022-3956(75)90026-6 · DOI · Paper page
- 10.2466/pr0.1983.53.2.479 · DOI
- DeJong R, 1989, Measurement of quality of life changes in patients with Alzheimer’s Disease., Clin Ther, 11, 545
- 10.1176/ajp.139.9.1136 · DOI
- Reisberg B, 1987, Behavioral symptoms in Alzheimer’s disease: phenomenology and treatment., J Clin Psychiatry, 48, 9
- 10.1212/WNL.50.5.1222 · DOI
- 10.1136/bmj.318.7184.633 · DOI · Paper page
- Selen A, 1988, Pharmacokinetics of tacrine in healthy subjects., Pharm Res, 5, 218
- 10.1023/A:1015933210803 · DOI
- 10.1016/0014-2999(89)90008-3 · DOI
- 10.1016/S0960-894X(00)80547-8 · DOI
- RogersSL YamanishiY YamatsuKBecker R Giacobini E eds.Cholinergic Basis for Alzheimer Therapy. 3rd ed. Boston: Birkhäuser 1991 E2020—The pharmacology of a piperidine cholinesterase inhibitor. p. 314–320. · DOI
- 10.2165/00002512-199710030-00007 · DOI
- Rogers SL, 1997, Pharmacokinetics of donepezil HCL (E2020) are unchanged in patients with impaired renal function., Clin Pharmacol Ther, 61, 217
- Anand R, 1996, Efficacy and safety results of the early phase studies with Exelon (ENA 713) in Alzheimer’s disease: an overview., J Drug Dev Clin Pract, 8, 109
- Anand R, 1996, Clinical development of Exelon (ENA‐713): the ADENA program., J Drug Dev Clin Pract, 8, 117
- 10.1016/S0079-6123(08)62429-2 · DOI
- 10.1016/0006-2952(75)90249-X · DOI
- 10.1111/j.1600-0773.1981.tb03256.x · DOI
- 10.1016/0140-6736(91)92656-M · DOI
- 10.1001/jama.1994.03510370037029 · DOI
- Farlow M, 1992, for the The Tacrine Study Group. A controlled trial of tacrine in Alzheimer’s disease., JAMA, 268, 2523, 10.1001/jama.1992.03490180055026 · DOI
- 10.1212/WNL.47.1.166 · DOI
- 10.1212/WNL.50.2.567 · DOI
- 10.1001/jama.280.20.1777 · DOI · Paper page
- 10.1159/000106895 · DOI
- 10.1212/WNL.50.1.136 · DOI · Paper page
- 10.1001/archinte.158.9.1021 · DOI
- 10.1016/S0924-977X(97)00079-5 · DOI
- Corey‐Bloom J, 1998, A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease., Int J Geriatr Psychopharmacol, 1, 55
- 10.1002/ddr.430190407 · DOI
- 10.1212/WNL.50.5.1214 · DOI
- 10.2105/AJPH.84.8.1261 · DOI
- BosanquetN MayJ JohnsonNAlzheimer’s Disease in the United Kingdom. Health Policy Review 1998 no. 12.
- 10.1001/archneur.1997.00550180013006 · DOI
- Friedhoff LT, 1997, Donepezil lengthens time to loss of activities of daily living inpatients with mild to moderate Alzheimer’s Disease—results of a preliminary evaluation., Neurology, 48, 2
- 10.1002/(SICI)1099-1166(199807)13:7<445::AID-GPS794>3.0.CO;2-E · DOI
Cited by
Sorted by citations
Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors
Jann, M. W., Shirley, K. L., & Small, G. W. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241100-00003 · Cited by 365
Phytochemicals as inhibitors of NF-κB for treatment of Alzheimer’s disease
Seo, E.-J., Fischer, N., & Efferth, T. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2017.11.030 · Cited by 265
The present and future of pharmacotherapy of Alzheimer's disease: a comprehensive review
Anand, A., Patience, A. A., Sharma, N., & Khurana, N. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.09.043 · Cited by 174
Hoss, A. G., Labadorf, A., Latourelle, J. C., Kartha, V. K., Hadzi, T. C., Gusella, J. F., MacDonald, M. E., Chen, J.-F., Akbarian, S., Weng, Z., et al. (2015) · BMC Medical Genomics · doi:10.1186/s12920-015-0083-3 · Cited by 151
Pharmacotherapy Evolution in Alzheimer’s Disease: Current Framework and Relevant Directions
Miculas, D. C., Negru, P. A., Bungau, S. G., Behl, T., Hassan, S. S. U., & Tit, D. M. (2022) · Cells · doi:10.3390/cells12010131 · Cited by 96
Metadata
- Authors
- McGleenon, Dynan, & Passmore
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 1999-10
- Volume
- 48
- Issue
- 4
- Pages
- 471-480
- ISSN
- 0306-5251
- 1365-2125
- Cited by
- 317
- References
- 4
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
